Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Filings indexed 1,011 across all filing types
Latest filing 2009-06-02 Director's Dealing
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
FORM 4 FOR 2009 OPTION GRANT
Director's Dealing
2009-06-02 English
FORM 4 FOR 2009 OPTION GRANT
Director's Dealing
2009-06-02 English
FORM 4 FOR 2009 OPTION GRANT
Director's Dealing
2009-06-02 English
FORM 4 FOR 2009 STOCK OPTION GRANT
Director's Dealing
2009-06-02 English
FORM 8-K FOR ALKERMES-TGC AMENDMENT #4
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an amendment to a material definitive agreement (an Exclusive License Agreement amendment). It does not contain financial statements or detailed financial performance data, nor is it an earnings release or annual/interim report. It is not a proxy, voting result, or management change announcement. The document is a regulatory filing reporting a material contract amendment. Given the nature of Form 8-K filings and the content, the appropriate classification is Regulatory Filings (RNS). The document length is short (3180 characters), consistent with a regulatory announcement rather than a full report.
2009-05-29 English
Director's Dealing 2009
Director's Dealing
2009-05-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.